Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016

Date: April 1, 2010
Pages: 41
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P2294BF6152EN
Leaflet:

Download PDF Leaflet

Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData, the industry analysis specialist’s new report, “Polycystic Ovarian Syndrome– Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global polycystic ovarian syndrome market. The report identifies the key trends shaping and driving the global polycystic ovarian syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global polycystic ovarian syndrome sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the global polycystic ovarian syndrome market. Its scope includes:
  • Annualized global polycystic ovarian syndrome market revenues data from 2001 to 2009, forecast for seven years to 2016.
  • Key geographies covered in this report are the US, the UK, Italy, Spain, Germany, France and Japan.
  • Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include fat breakdown inhibitors, estrogen antagonists, female gamete enhancers, insulin secretion stimulators, gastric lipase inhibitor HMG CoA inhibitors.
  • Analysis of the current and future market competition in the global polycystic ovarian syndrome market. Key market players covered include Sanofi Aventis, Bristol Myers Squibb, Novartis Pharmaceuticals, Sandoz Inc, Genpharm Inc, Ivax Pharmaceuticals Inc, Barr Laboratories Inc, Par Pharmaceuticals Inc. Genpharm Inc, Merck CoA and Catalysis SL.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future polycystic ovarian syndrome market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global polycystic ovarian syndrome market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global polycystic ovarian syndrome market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global polycystic ovarian syndrome market landscape? – Identify, understand and capitalize.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 POLYCYSTIC OVARIAN SYNDROME MARKET: MARKET CHARACTERIZATION

2.1 Market Overview
2.2 Polycystic Ovarian Syndrome Market Size
2.3 Polycystic Ovarian Syndrome Market forecast and CAGR
2.4 Drivers and Barriers for Polycystic Ovarian Syndrome Market
  2.4.1 Drivers for Polycystic Ovarian Syndrome market
  2.4.2 Barriers for Polycystic Ovarian Syndrome market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 POLYCYSTIC OVARIAN SYNDROME MARKET: COMPETITIVE ASSESSMENT

3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for The Marketed Drugs For Polycystic Ovarian Syndrome
  3.3.1 Clomid
3.4 Product Profile for Off-Label Drugs for Polycystic Ovarian Syndrome
  3.4.1 Metformin
  3.4.2 Letrozole
  3.4.3 Flutamide
3.5 Key Takeaway

4 POLYCYSTIC OVARIAN SYNDROME MARKET: PIPELINE ASSESSMENT

4.1 Overview
4.2 Strategic Pipeline Assessment
  4.2.1 Technology Trends Analytic Framework
4.3 Profile of Pipeline Molecules in Clinical Development
  4.3.1 Metformin + exenatide
  4.3.2 Follitropin alfa liquid formulation
  4.3.3 Human Gonadotropin Hormone
  4.3.4 Simvastatin
  4.3.5 Orlistat
  4.3.6 Clomiphene citrate + raloxifene
  4.3.7 Oral DCI
  4.3.8 Sibutramine + Loestrin (ethinyl estradiol)
  4.3.9 Leuprolide acetate + Spironolactone
  4.3.10 Oral Cinnamon Extract
  4.3.11 Oral contraceptive
  4.3.12 Dietary Supplement: Diamel
  4.3.13 Dietary Supplement: Flaxeed
  4.3.14 Dietary Supplement: Alpha Lipoic Acid
  4.3.15 Dietary Supplement: Vitamin D
4.4 Polycystic Ovarian Syndrome Market – Clinical Pipeline by Mechanism of Action
4.5 Polycystic Ovarian Syndrome Pipeline – Pipeline by Clinical Phases of Development
  4.5.1 Polycystic Ovarian Syndrome Market – Phase III Clinical Pipeline
  4.5.2 Polycystic Ovarian Syndrome Market – Phase II Clinical Pipeline
  4.5.3 Polycystic Ovarian Syndrome Market – Phase I Clinical Pipeline
4.6 Key takeaway

5 POLYCYSTIC OVARIAN SYNDROME MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

6 POLYCYSTIC OVARIAN SYNDROME MARKET: FUTURE PLAYERS IN POLYCYSTIC OVARIAN SYNDROME MARKET

6.1 Merck KGaA
  6.1.1 Company Overview
  6.1.2 Business Description
  6.1.3 Female Sexual Dysfunction Portfolio
6.2 Catalysis SL
  6.2.1 Company overview
  6.2.2 Female Sexual Dysfunction Portfolio

7 POLYCYSTIC OVARIAN SYNDROME MARKET: APPENDIX

7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
  7.3.1 Coverage
  7.3.2 Secondary Research
  7.3.3 Forecasting
  7.3.4 Primary Research
  7.3.5 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

LIST OF TABLES

Table 1: Polycystic Ovarian Syndrome Market, Revenue ($m), 2001-2009
Table 2: Polycystic Ovarian Syndrome Market, Revenue ($m), 2009-2016
Table 3: Major Marketed Products Comparison in the Polycystic Ovarian Syndrome Market, 2010
Table 4: Polycystic Ovarian Syndrome Market– Phase III Clinical Pipeline, 2010
Table 5: Polycystic Ovarian Syndrome Market- Phase II Clinical Pipeline, 2010
Table 6: Polycystic Ovarian Syndrome Market-Phase I Clinical Pipeline, 2010
Table 7: Merck Pharmaceuticals – Female Sexual Dysfunction Marketed Products, 2010
Table 8: Merck Pharmaceuticals – Female Sexual Dysfunction Pipeline Products, 2010
Table 9: Catalysis SL – Female Sexual Dysfunction Marketed Products, 2010
Table 10: Catalysis SL – Female Sexual Dysfunction Pipeline Products, 2010

LIST OF FIGURES

Figure 1: Polycystic Ovarian Syndrome Market, Revenue ($m), 2001-2009
Figure 2: Polycystic Ovarian Syndrome Market, Revenue ($m), 2009-2016
Figure 3: Opportunity and Unmet Need for Polycystic Ovarian Syndrome Market, 2010
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Polycystic Ovarian Syndrome Market, 2010
Figure 5: Technology Trends Analytic Framework of the Polycystic Ovarian Syndrome Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the Polycystic Ovarian Syndrome Pipeline – Description, 2010
Figure 7: Polycystic Ovarian Syndrome Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 8: Polycystic Ovarian Syndrome Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in Polycystic Ovarian Syndrome Market, 2010
Figure 10: GlobalData Methodology, 2010
Figure 11: GlobalData Market Forecasting Model, 2010

COMPANIES MENTIONED

Merck KGaA
Catalysis SL

Ask Your Question

Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: